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Abstract Patients with nodal positive prostate cancers are
an important cohort with poorly defined risk factors. CD10
is a cell surface metallopeptidase that has been suggested to
play a role in prostate cancer progression. CD10 expression
was evaluated in 119 nodal positive prostate cancer
patients using tissue microarrays constructed from pri-
mary tumors and lymph node metastases. All patients
underwent radical prostatectomy and standardized ex-
tended lymphadenectomy. They had no neoadjuvant
therapy and received deferred androgen deprivation. In
the primary tumor, high CD10 expression was signifi-
cantly associated with earlier death from disease when
compared with low CD10 expression (5-year survival
73.7% vs. 91.8%; p=0.043). In the metastases, a high
CD10 expression was significantly associated with larger
total size of metastases (median 11.4 vs. 6.5 mm; p=
0.015), earlier death of disease (5-year survival 71.5% vs.
87.3%; p=0.017), and death of any cause (5-year survival
70.0% vs. 87.2%; p=0.001) when compared with low
CD10 expression. CD10 expression in the metastases
added independent prognostic information for overall
survival (p=0.029) after adjustment for Gleason score of
the primary tumor, nodal tumor burden, and resection
margins. In conclusion, a high CD10 expression in
prostate cancer predicts early death. This information is
inherent in the primary tumors and in the lymph node
metastases and might help to personalize patient management.
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Introduction
Prostate cancer is the second most frequently diagnosed
cancer and the sixth leading cause of cancer death in males
worldwide [1]. Surgically treated lymph node positive
prostate cancer patients are an important subpopulation
having a similar incidence in the US like men with
esophageal, gastric, or testicular cancer [2] and showing a
considerable clinical, morphological, and biological hetero-
geneity of disease [3]. For these men, risk factors predicting
fatal outcome are poorly defined.
CD10, also known as neutral endopeptidase, might be a
molecular biomarker with the ability to predict death in
prostate cancer. CD10 is a zinc-dependent cell surface
metallopeptidase which is widely expressed in epithelial
cells of various sites including kidney, breast, lung,
intestine, and prostate [4]. CD10 contains a large extracel-
lular domain known to process a variety of more than 20
neuropeptides by enzymatic cleavage [4] thus modifying
the pericellular concentration of specific peptides available
for receptor binding. There is evidence that peptide-
mediated cell growth can be suppressed or promoted by
CD10 expression [5]. More recently, the effects of CD10 on
growth and migration of cells have been reported which are
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independent from its enzymatic property [6]; however, the
entire biological significance of CD10 is still largely
unknown. The potential of CD 10 expression in prostate
cancer to predict prostate-specific antigen (PSA) recurrence
has been evaluated in few cohorts with conflicting results
[7–11]. Importantly, survival data obtained from our cohort
of 2,385 hormone naive prostate cancer patients treated by
radical prostatectomy indicate early PSA failure for patients
with CD10 expression [11]. This contrasts with the tumor-
suppressing functions of CD10 in prostate cancer observed
in functional studies [6]. Here, we tested the potential of
CD10 to predict death in another well-defined cohort of




One hundred and nineteen consecutive prostate cancer
patients without clinical evidence of metastases (physical
examination, abdominal/pelvic computerized tomography,
bone scan, and chest X-ray) but with nodal metastases upon
histological examination of the lymphadenectomy speci-
mens were studied. All patients underwent a standardized
bilateral extended pelvic lymphadenectomy and radical
prostatectomy as a single procedure between February
1989 and December 2006 at the Department of Urology,
University of Bern. They received no neoadjuvant therapy
and were followed prospectively. No adjuvant therapy,
androgen deprivation in particular, was recommended until
symptomatic disease progression had occurred.
Surgical technique of lymphadenectomy
Bilateral pelvic lymphadenectomy was performed in all
patients as previously described [12]. Briefly, lymph node
dissection was performed along the external iliac vein down
to the deep circumflex iliac vein and femoral canal with the
bifurcation of the common iliac artery as proximal limit of
the surgical field. Next, the obturator fossa was cleared of
all tissues except the nerve and vessels. Lastly, the
lymphatic tissue along the medial and lateral aspect of the
internal iliac artery and vein was removed. The three tissue
samples from each side were submitted separately for
examination.
Pathology
All prostatectomy and lymphadenectomy specimens were
processed at the Institute of Pathology, University of Bern
as previously described [3, 13]. For this study, all slides
were re-evaluated by experienced genitourinary patholo-
gists (AF, CR, and NS). All Gleason patterns present in the
primary tumors and lymph node metastases were tightly
encircled for subsequent tissue microarray (TMA) con-
struction.
The prostates were totally embedded. The following
microscopic tumor characteristics were noted: type, Glea-
son score, and tumor stage. Tumor volume was estimated
by multiplying the percentage of the specimen involved by
cancer by the prostate volume [3, 13]. The diameter of each
lymph node metastasis was measured. The seventh edition
of the TNM classification [14] was used for staging.
TMA
The TMA [15] was constructed with tissue cores of 0.6 mm
in diameter. Each Gleason pattern present in every primary
tumor and in the matched lymph node metastases as well as
non-neoplastic prostate tissue (peripheral zone) is repre-
sented by one tissue core. This TMA contains 403 punch
biopsy specimens from prostates (mean per patient, 3.3;
range, 2–4) and 167 from lymph node metastases (mean per
patient, 1.4; range, 1–3). The distribution of these samples in
the prostates is as follows: normal prostate tissue (n=119),
Gleason pattern 3 (n=101), Gleason pattern 4 (n=112), and
Gleason pattern 5 (n=71). The distribution of these samples
in the metastases is as follows: Gleason pattern 3 (n=35),
Gleason pattern 4 (n=103), and Gleason pattern 5 (n=29).
Immunohistochemistry
Freshly cut TMA sections were analyzed in 1 day in one
experiment. High-temperature pretreatment of slides was
done in steam with target retrieval solution, pH 9 (Dako,
Glostrup, Denmark). CD10 expression was assessed using
the monoclonal antibody CD10 (clon 56C6; Novocastra,
Newcastle-upon-Tyne, UK). Optimal staining was achieved
at 1:50 antibody dilution. Bound primary antibodies were
visualized using the Envision Plus system (Dako, Glostrup,
Denmark). CD10 expression was observed on the cell
membrane and in the cytoplasm (Fig. 1). Tumors could be
heterogeneous in subcellular CD10 expression between
different spots. Therefore, only the percentage of positive
tumor cells per patient in the primary tumor and the lymph
node metastases was determined. The percentage of CD10
positive tumor cells was determined for each Gleason
pattern averaged over all primary tumors and nodal
metastases, respectively.
Statistical analysis
CD10 expression in normal prostate, primary cancer, and
metastases was compared using Kruskal–Wallis test.
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Friedman Test was used to evaluate differences between
Gleason patterns 3, 4, and 5 within primary tumors and
lymph node metastases, the Wilcoxon two-sample test
compared expression in primary tumors and metastases
stratified by the Gleason patterns. CD10 expression was
correlated with (a) quantitative tumor features using the t
test (age) or Wilcoxon test (tumor volume, total size, and
number of metastases) and (b) categorical tumor features
using Fisher’s exact test. Receiver-operating characteristic
curves [16] were used to determine the optimal cut-off
values for high (greater than 40% positive cells) and low
(40% positive cells or less) CD10 expression in both the
primary tumors and lymph node metastases. Outcome was
analyzed for biochemical recurrence-free, disease-specific
(DSS), and overall (OS) survival defined as the intervals
from surgery to the date of biochemical recurrence (PSA
failure defined as values >0.2 ng/ml), death from prostate
carcinoma, and death from any cause, respectively.
Patients without event for the respective endpoints were
censored at the date of last follow-up. The above time-to-
events were compared between groups using log-rank test.
P values less than 0.05 were considered significant for all
tests. After verification of the proportional hazards
assumption, multiple Cox regression analysis was used
for all three endpoints to determine the prognostic impact
of CD10 expression in primary tumors and metastases
controlling for independent risk factors determined previously
in a subset of this cohort [3, 13]: Gleason score of the primary
tumor (6/7/8 vs. 9/10 grouped according to similar survival
curves between the clustered subsets) and lymph node tumor
burden reflected by the total diameter of all nodal metastases
(median value, 7.5 mm, was used as cut-off).
Results
Characteristics of patients, prostatectomy specimens,
lymphadenectomy specimens, and lymph node metastases
Baseline data of the cohort are given in Table 1.
Expression of CD10 in normal prostate, primary tumors,
and lymph node metastases considering the Gleason
patterns
CD10 expression was lost in primary tumors (63.3%) and
lymph node metastases (46.9%) when compared with
normal prostate glands (90.1%; p<0.001). No significant
difference was detected between the different Gleason
patterns (GP) in the primary tumors (GP3, 60.1%; GP4,
Fig. 1 CD10 expression in pri-
mary prostate cancer (a, b) and
in lymph node metastases (c, d).
a Few neoplastic cells with
CD10 expression at the apical
membrane and in the cytoplasm
and immunoreactivity in the
stroma. b Virtually all neoplastic
cells with membranous and cy-
toplasmic CD10 expression. c
No CD10 expression in the
neoplastic cells. d Strong cyto-
plasmic CD10 expression in the
neoplastic cells
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61.0%; GP5, 68.8%; p=0.198) and in the metastases (GP3,
65.3%; GP4, 38.2%; GP5, 53.7%; p=0.058).
Correlations of CD10 expression in primary tumors
and metastases with clinicopathological tumor
characteristics
In the primary tumors, there was no trend for the association
of CD10 with Gleason score, tumor stage, or tumor volume.
In the metastases, high CD10 expression was significantly
associated with larger total size of metastases (median 11.4 vs.
6.5 mm; p=0.015) but not with the median number of
positive nodes (2.5 vs. 2.0; p=0.169) or lymph node
Gleason score.
Univariate survival analysis according to CD10 expression
In primary prostate cancer, high CD10 expression (average
percentage of CD10 positive cancer cells, 74%) signifi-
cantly predicted early death of disease (p=0.043; Fig. 2)
with a 5-year DSS rate of 73.7%, while patients with low
CD10 expression (average percentage of CD10 positive
cancer cells, 20%) had a 5-year DSS rate of 91.8%. In the
metastases, high CD10 expression (average percentage of
CD10 positive cancer cells, 76%) was a significant adverse
risk factor for DSS (p=0.017) and OS (p=0.001) compared
with low CD10 expression (average percentage of CD10
positive cancer cells, 11%; 5-year DSS, 71.5% vs. 87.3%;
5-year OS, 70.0% vs. 87.2%; Fig. 2). The difference in PSA
recurrence-free survival between patients with high and low
CD10 expression was not significant (Fig. 2).
Multivariate analysis
Two separate multivariate analyses tested the prognostic
impact of CD10 expression in the primary tumors and in
the metastases, respectively, after adjusting for the prog-
nostic effects of size of metastases and Gleason score of the
primary tumor (Table 2). Patients with high CD10
expression in the metastases had a nearly tripled mortality
(hazard ratio 2.81) compared with patients with low CD10
expression. This difference added an independent prognos-
tic information (p=0.029). The strongest prognostic factor
for all endpoints was nodal tumor burden reflected by the
total diameter of all metastases.
Discussion
Functional studies in single prostate cancer cell lines
suggested a tumor suppressor function of CD10 [6].
However, when prostate cancer tissues were evaluated,
Patient data (n=119)
Age (median, range) at surgery (years) 65 (45–75)
Follow-up (median, range) (years) 5.9 (1–15.2)
Patients with biochemical failure at last follow-up (n) 103
Patients dead of disease at last follow-up (n) 33






Prostate carcinoma volume (median, range) (cm3) 12.6 (0.66-127)
Gleason score
6 (n) 12
7 (3+4; 4+3) (n) 63 (33; 30)
8 (n) 21
9 (n) 23
Positive resection margins (n) 84
Lymphadenectomy data
Total number of evaluated nodes (n) 2,794
Total number of evaluated lymph node metastases (n) 382
Evaluated nodes per patient (median, range) (n) 22 (9–68)
Positive nodes per patient (median, range) (n) 2 (1–24)
Total diameter of metastases per patient (median, range) (mm) 7.5 (0.3–204)
Table 1 Characteristics of 119
surgically treated prostate cancer
patients with pelvic lymph node
metastases
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results were conflicting. Depending on the cohort, CD10
expression was considered as unfavorable [7, 11], favorable
[9], or no risk factor [8, 10] for PSA recurrence after
therapy. The comparability of these results, however, is
limited due to large differences between the evaluated
cohorts. The better outcome for CD10 positive patients
reported by Osman et al. [9] was detected in a cohort of
mainly African–American men with significant race-
dependent differences in CD10 expression potentially
impacting on results. Zellweger et al. [10] evaluated a
cohort of heterogeneously treated patients including
patients with hormonal therapy, which is known to suppress
CD10 expression in prostate cancer via androgen respon-
sive elements [17]. Recent data showing CD10 expression
as an independent adverse risk factor for PSA recurrence-
free survival in a surgically treated, hormone naive
Fig. 2 Survival analysis accord-
ing to CD10 expression in pri-
mary prostate cancer (left) and
lymph node metastases (right).
Overall (first row) and disease-
specific (second row) survivals
are significantly better in
patients with low CD10 expres-
sion in primary tumors or me-
tastases when compared to
patients with high expression in
these tumor components
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population of 2,385 prostate cancer patients [11] were in
accordance with findings reported by Dall’Era et al. [7].
In this study, we extended the analysis of CD10 in
prostate cancer in two respects: first, we tested the potential
of CD10 to predict fatal outcome; second, the prognostic
relevance was determined in a particular cohort of hormone
naive, surgically treated patients with lymph node metasta-
ses. Importantly, patients with high CD10 expression, no
matter if in the primary prostate cancer or in the metastasis,
experience early death. High CD10 expression in the lymph
node metastases added independent prognostic information
and was associated with a nearly tripled risk of dying
compared with patients with low CD10 expression. This is
of considerable clinical interest because (a) prognostic
factors are only poorly defined in surgically treated lymph
node positive prostate cancer what is an important disease
with a similar incidence in US American men as esopha-
geal, gastric, or testicular cancer [2]; and (b) death is a more
robust endpoint than PSA recurrence. The clinical course
following PSA recurrence after radical prostatectomy is
extremely variable with rapid progression in some men and
an indolent course in others [18]. By contrast, death is an
outcome measure of the “true” clinical course. Therefore,
our data suggest that the natural history of disease in
surgically treated lymph node positive prostate cancer can
be accurately predicted by CD10 expression.
The prognostic potential of biomarker expression in the
different tumor components of lymph node positive cancer
has been compared in only few tumors [19–21] including
prostate cancers [22–25]. In case of successful survival
stratification, the metastasizing tumor component but not
the primary tumor [19, 20, 22] or both tumor components
[21, 23, 25] may harbor the prognostic information. In
prostate cancer, CD10 expression in both tumor compo-
nents, the primary cancers and the nodal metastases,
predicts survival significantly. This is clinically relevant
for lymph node positive patients treated by surgery because
their clinical course can be predicted more precisely and
adjuvant therapies might be scheduled accordingly.
Moreover, risk assessment in patients with metastasized
prostate cancers not qualifying for local therapies with
curative intent might be improved by CD10 determina-
tion in core needle biopsies of the primary tumor.
Important risk factors in this population like metastatic
tumor burden and Gleason score of the primary tumor [3]
can only be imprecisely determined and, therefore, the
prognostic information by CD10 expression might even be
superior. In this context, it is noteworthy that the tumor
amount analyzed on TMAs is highly comparable to the
one in the core needle biopsies so that prognostic markers
identified in prostate cancer TMAs may also be relevant in
the biopsy setting.
Table 2 Separate multivariate analyses for the prognostic impact of CD10 expression in primary prostate cancer (upper half) and lymph node
metastases (lower half), respectively, after adjustment for total size of metastases, Gleason score of primary tumor, and resection margin
Parameter Cut-off Overall survival Disease-specific survival Recurrence-free survival
HR (95%CI) P HR (95%CI) P HR (95%CI) P
CD10 in primary tumor Low 1.0 0.425 1.0 0.296 1.0 0.996
High 1.43 (0.6–3.5) 1.76 (0.6–5.1) 1.0 (0.6–1.6)
Total diameter of metastases <7.5 mm 1.0 <0.001 1.0 0.006 1.0 0.016
≥7.5 mm 3.76 (1.7–8.2) 3.45 (1.4–8.3) 1.7 (1.1–2.6)
Gleason score 6 to 8 1.0 0.292 1.0 0.069 1.0 0.488
9 to 10 1.49 (0.7–3.1) 2.05 (1.0–4.4) 1.2 (0.7–2.0)
Resection margin Negative 1.0 0.468 1.0 0.724 1.0 0.289
Positive 1.34 (0.6–3.0) 1.17 (0.5–2.7) 1.29 (0.8–2.1)
CD10 in metastases Low 1.0 0.029 1.0 0.227 1.0 0.865
High 2.81 (1.1–7.1) 1.92 (0.7–5.5) 1.04 (0.7–1.7)
Total diameter of metastases <7.5 mm 1.0 0.003 1.0 0.007 1.0 0.061
≥7.5 mm 5.18 (1.7–15.3) 7.66 (1.7–34.0) 1.59 (1.0–2.6)
Gleason score 6 to 8 1.0 0.532 1.0 0.075 1.0 0.789
9 to 10 1.31 (0.6–3.1) 2.33 (0.9–5.9) 1.08 (0.6–1.9)
Resection margin Negative 1.0 0.462 1.0 0.825 1.0 0.133
Positive 1.45 (0.5–3.9) 1.14 (0.4–3.5) 1.5 (0.9–2.5)
HR hazard ratio, CI confidence interval
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CD10 expression in lymph node metastases of prostate
cancer is positively correlated with nodal tumor burden.
The pathophysiological link, however, is obscure. Conceiv-
ably, CD10 in prostate cancer metastases inactivates
antiproliferative peptides thus promoting tumor growth
what would be in line with the well-known enzymatic
property of CD10. Alternatively, the enzymatic activity of
CD10 could promote tumor growth by conversion of a pro-
peptide into a biologically active, stimulatory form. These
basic mechanisms have been suggested for ectopeptidases
in general [26] and might also apply to CD10 function in
prostate cancer in vivo. CD10 function depends on tissue
type [7] indicated by specific tumor cell lines promoted [5]
or suppressed [27] by CD10. Accordingly, CD10 expres-
sion can be a favorable [28] or an unfavorable [29]
prognostic factor dependent on the cancer type.
Finally, CD10 expression in prostate cancer might also be
therapeutically relevant. Newly developed CD10 inhibitors
[30] may complement established therapies to counteract the
unfavorable effects of CD10 on survival. Alternatively,
peptide prodrugs might be applied which are enzymatically
activated by CD10 expression on tumor cells. This antitumor
effect has been applied successfully in a xenograft model
using a CD10-overexpressing prostate cancer cell line [31].
In conclusion, CD10 expression in nodal positive prostate
cancer predicts early death. This information may help to
better predict survival individually and to personalize adjuvant
therapies, thus improving patient management.
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